MORE INFO
Executive Summary
Mycophenolate synergistically kills cancer cells with cytotoxic cancer drugs
Mucoadhesive patch reverses dysplasia
Executive Summary
CADRx Precision Medicines is a biopharmaceutical company developing biocompatible and biodegradable, unidirectional topical drug delivery platforms, whose geometries & release kinetics allow for a tunable pharmacokinetic profile for mucosal & dermal applications. These platforms can achieve bolus release followed by steady state release, keeping local drug levels within a therapeutic window for a precise duration, while minimizing systemic toxicities. CADRx technology can be leveraged to address unmet medical needs by repurposing novel drug combinations, where there are low regulatory & capital hurdles by leveraging toxicity data for FDA approved reference products.
Mucoadhesive patch reverses dysplasia
Mycophenolate synergistically kills cancer cells with cytotoxic cancer drugs
Mucoadhesive patch reverses dysplasia
R
Designing a Mucoadhesive ChemoPatch to Ablate Oral Dysplasia for Cancer Prevention.
Liu, X., Li, Q., Wang, Y., Crawford, M., Bhupal, P. K., Gao, X., Xie, H., Liang, D., Cheng, Y.-S. L., Liu, X., Tsai, R. Y. L., Small 2022, 18, 2201561. https://doi.org/10.1002/smll.202201561
Mycophenolate synergistically kills cancer cells with cytotoxic cancer drugs
Mycophenolate synergistically kills cancer cells with cytotoxic cancer drugs
Mycophenolate synergistically kills cancer cells with cytotoxic cancer drugs
GTP depletion synergizes the anti-proliferative activity of chemotherapeutic agents in a cell type-dependent manner.
Tao Lin, Lingjun Meng, Robert Y.L. Tsai
Biochemical and Biophysical Research Communications, Volume 414, Issue 2, 2011, Pages 403-408
Targeted oral delivery of mycophenolate is feasible
Oxaliplatin can be directionally delivered to the tongue
Mycophenolate synergistically kills cancer cells with cytotoxic cancer drugs
Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid
Xiuqing Gao, Lei Wu, Robert Y. L. Tsai, Jing Ma, Xiaohua Liu, Diana S.-L. Chow, Dong Liang, Huan Xie
Pharmaceutics 2021, 13(4), 574; https://doi.org/10.3390/pharmaceutics13040574
Oxaliplatin can be directionally delivered to the tongue
Oxaliplatin can be directionally delivered to the tongue
Oxaliplatin can be directionally delivered to the tongue
Determination of Oxaliplatin by a UHPLC-MS/MS Method: Application to Pharmacokinetics and Tongue Tissue Distribution Studies in Rats
Gao X, Tsai RYL, Ma J, et al. Pharmaceuticals (Basel). 2021;15(1):52. 2021 Dec 31. doi:10.3390/ph15010052
Tissue distribution of mycophenolate
Oxaliplatin can be directionally delivered to the tongue
Oxaliplatin can be directionally delivered to the tongue
Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats.
Xiuqing Gao, Robert Y.L. Tsai, Jing Ma, Parnit K. Bhupal, Xiaohua Liu, Dong Liang, Huan Xie
Journal of Chromatography B, Volume 1136, 1 Jan. 2020, 121930
Patent on MPA synergistic modalities US Patent 9,492,426
COMING SOON: Idealized Target Product Profile for a Drug to Treat Leukoplakia and Prevent Oral Cance
COMING SOON: Idealized Target Product Profile for a Drug to Treat Leukoplakia and Prevent Oral Cance
In some embodiments, the present disclosure provides methods of treating a tumor in a subject. In some embodiments, the methods may include a step of administering to the subject a therapeutic composition that comprises: (a) mycophenolic acid, an analogue thereof, or a derivative thereof; and (b) at least one anti-neoplastic agent.
COMING SOON: Idealized Target Product Profile for a Drug to Treat Leukoplakia and Prevent Oral Cance
COMING SOON: Idealized Target Product Profile for a Drug to Treat Leukoplakia and Prevent Oral Cance
COMING SOON: Idealized Target Product Profile for a Drug to Treat Leukoplakia and Prevent Oral Cance
Most chemoprevention products fail because of tolerability rooted in off target toxicities and suboptimal pharmacology, or challenges with clincial outcome assessment.